Shaperon Inc. (KOSDAQ:378800)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,645.00
-137.00 (-7.69%)
At close: Apr 2, 2026
Market Cap76.07B -20.3%
Revenue (ttm)227.80M +1,186.7%
Net Income-15.53B
EPS-480.00
Shares Out46.24M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,006,720
Average Volume792,719
Open1,782.00
Previous Close1,782.00
Day's Range1,626.00 - 1,828.00
52-Week Range1,523.00 - 4,020.00
Beta0.12
RSI52.64
Earnings DateNov 14, 2025

About Shaperon

Shaperon Inc. develops therapies based on GPCR19-inflammasome inhibitor platform and NanoMab antibody platform for immune diseases. It offers NuGel which blocks the root cause of atopic dermatitis that is in Phase 2 clinical trials; NuDifin that calms wound inflammation and accelerates the regeneration of tissue; NuRalin indicated for atopic dermatitis; NuAreatin for the treatment of alopecia areata. The company also provides NuCerin, a pill designed to reduce neuroinflammation; NuSepin, which alleviates excessive systemic inflammation; and NuP... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2008
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 378800
Full Company Profile

Financial Performance

In 2025, Shaperon's revenue was 227.80 million, an increase of 1186.71% compared to the previous year's 17.70 million. Losses were -15.53 billion, 4.19% more than in 2024.

Financial Statements